Answers are grounded in this paper and cite their sources.
Pulmonary fibrosis (PF), particularly idiopathic pulmonary fibrosis (IPF), frequently coexists with pulmonary and extrapulmonary conditions, including cardiovascular disease, gastroesophageal reflux disease (GERD), pulmonary hypertension (PH), metabolic disorders, lung cancer, and obstructive or emphysematous lung disease. These comorbidities can substantially affect disease course, prognosis, and therapeutic decision‐making. Growing evidence suggests that their coexistence with PF is not simply coincidental, but may reflect overlapping pathological processes involving chronic inflammation and immune dysregulation, oxidative and mitochondrial stress, endothelial dysfunction, cellular senescence, metabolic reprogramming, and maladaptive tissue repair. Occupational inhalational exposures may influence PF development and associated comorbidity phenotypes through recurrent alveolar epithelial injury, oxidative stress, and persistent inflammatory responses. These effects may be modified by smoking, aging, genetic susceptibility, metabolic status, and other host characteristics. This review examines the links among external exposures, shared pathological processes, and major pulmonary and extrapulmonary comorbidities of PF, with emphasis on epidemiological evidence, bidirectional relationships, and disease‐specific mechanisms. Particular attention is given to occupational inhalational exposures and their potential contribution to comorbidity heterogeneity, as well as to the clinical value of integrating structured exposure history with comorbidity assessment and disease phenotyping.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: